|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Drug** | **Author, Year** | **Dose** | **Outcome [unit]** | **FU, mos** | **IG N** | **IG N(%) at MN rand** | **IG N (%) FU** | **CG N** | **CG N(%) at MN rand** | **CG N (%) FU** | **Calculated RR (95% CI)\*** |
| **Liraglutide** | Wadden, 2013312 | 3.0mg QD | Maintenance of 5% weight loss [n] | 13 | 207 | 207 (100%) | 105 (50.5%) | 206 | 206 (100%) | 45 (21.8%) | OR: 3.90 (2.40 to 6.10); p≤0.0001 |
| 3.0mg QD | Maintenance of 10% weight loss [n] | 13 | 207 | NR | 54 (26.1%) | 206 | NR | 13 (6.3%) | OR: 5.30 (2.80 to 10.10); p≤0.0001 |
| **Orlistat** | Richelsen, 2007287 | 120mg TID | Maintenance of 5% weight loss [n] | 12 | 153 | 153 (100%) | 130 (85.0%) | 156 | 156 (100%) | 112 (72.0%) | 1.18 (1.05 to 1.33); p≤0.001 |
| 120mg TID | Maintenance of 5% weight loss [n] | 36 | 153 | 153 (100%) | 102 (67.0%) | 156 | 156 (100%) | 87 (56.0%) | 1.20 (1.00 to 1.43); p≤0.05 |
| 120mg TID | Maintenance of 10% weight loss [n] | 36 | 153 | NR | 52 (34.0%) | 156 | NR | 45 (29.0%) | 1.18 (0.85 to 1.64); p=NS, NR |

\* Study-reported adjusted between group difference in mean change reported if available; otherwise, calculated unadjusted between group difference.

**Abbreviations**: CG = control group; CI = confidence interval; FU = followup; IG = intervention group; mg = milligrams; mos = months; NR = not reported; NS = not statistically significant; rand = randomization; QD = once a day; rand = randomization; RR = risk ratio; TID = three times a day